Erythropoietin stimulation agents significantly improves outcome in lower risk MDS

H K G Garelius; Alexandra Gwen Smith; Timothy Charles Bagguley; Adele Taylor; Pierre  Fenaux; D. Bowen; Argyris Symeonidis; M MIttelmann; R Stauder; Jaroslav  Čermák; Guillermo Sanz; Saskia Langemeijer; Luca  Malcovati; Ulrich  Germing; Raphael Itzykson; Agnès Guerci-Bresler; Dominic Culligan; Ioannis Kotsianidis; Karin A. Koinig; Corine van Marrewijk; Simon Crouch; Theo de Witte; E Hellstrom-Lindberg

doi:10.1097/01.hs9.0000843564.40783.b4

Erythropoietin stimulation agents significantly improves outcome in lower risk MDS

H K G Garelius, Alexandra Gwen Smith, Timothy Charles Bagguley, Adele Taylor, Pierre Fenaux, D. Bowen, Argyris Symeonidis, M MIttelmann, R Stauder, Jaroslav Čermák, Guillermo Sanz, Saskia Langemeijer, Luca Malcovati, Ulrich Germing, Raphael Itzykson, Agnès Guerci-Bresler, Dominic Culligan, Ioannis Kotsianidis, Karin A. Koinig, Corine van MarrewijkSimon Crouch, Theo de Witte, E Hellstrom-Lindberg

Health Sciences

Research output: Contribution to journal › Meeting abstract › peer-review

Abstract

The EUMDS Registry started in 2008 as a prospective, non-interventional longitudinal study, enrolling newly diagnosed patients with IPSS low or intermediate-1 MDS from 16 European countries and Israel.

Original language	English
Article number	S168
Pages (from-to)	69-70
Journal	HemaSphere
Volume	6
DOIs	https://doi.org/10.1097/01.hs9.0000843564.40783.b4
Publication status	Published - Jun 2022
Event	EHA2022 Hybrid Congress - Messe Wien Exhibition & Congress Center, Vienna, Austria Duration: 9 Jun 2022 → 12 Jun 2022 https://ehaweb.org/congress/eha2022-hybrid/general-information/

Bibliographical note

Access to Document

10.1097/01.hs9.0000843564.40783.b4

S168__ERYTHROPOIETIN_STIMULATION_AGENTS.69
© 2022 The Author(s). Published by Wolters Kluwer Health, Inc.
Final published version, 252 KBLicence: CC BY

Cite this

Garelius, H. K. G., Smith, A. G., Bagguley, T. C., Taylor, A., Fenaux, P., Bowen, D., Symeonidis, A., MIttelmann, M., Stauder, R., Čermák, J., Sanz, G., Langemeijer, S., Malcovati, L., Germing, U., Itzykson, R., Guerci-Bresler, A., Culligan, D., Kotsianidis, I., Koinig, K. A., ... Hellstrom-Lindberg, E. (2022). Erythropoietin stimulation agents significantly improves outcome in lower risk MDS. HemaSphere, 6, 69-70. Article S168. https://doi.org/10.1097/01.hs9.0000843564.40783.b4

@article{cb5f8278a46144ba8d257b96062e08e3,

title = "Erythropoietin stimulation agents significantly improves outcome in lower risk MDS",

abstract = "The EUMDS Registry started in 2008 as a prospective, non-interventional longitudinal study, enrolling newly diagnosed patients with IPSS low or intermediate-1 MDS from 16 European countries and Israel.",

author = "Garelius, {H K G} and Smith, {Alexandra Gwen} and Bagguley, {Timothy Charles} and Adele Taylor and Pierre Fenaux and D. Bowen and Argyris Symeonidis and M MIttelmann and R Stauder and Jaroslav {\v C}erm{\'a}k and Guillermo Sanz and Saskia Langemeijer and Luca Malcovati and Ulrich Germing and Raphael Itzykson and Agn{\`e}s Guerci-Bresler and Dominic Culligan and Ioannis Kotsianidis and Koinig, {Karin A.} and {van Marrewijk}, Corine and Simon Crouch and {de Witte}, Theo and E Hellstrom-Lindberg",

note = "{\textcopyright} 2022 The Author(s). Published by Wolters Kluwer Health, Inc.; EHA2022 Hybrid Congress ; Conference date: 09-06-2022 Through 12-06-2022",

year = "2022",

month = jun,

doi = "10.1097/01.hs9.0000843564.40783.b4",

language = "English",

volume = "6",

pages = "69--70",

journal = "HemaSphere",

issn = "2572-9241",

publisher = "Wolters Kluwer Health",

url = "https://ehaweb.org/congress/eha2022-hybrid/general-information/",

}

Garelius, HKG, Smith, AG , Bagguley, TC , Taylor, A, Fenaux, P, Bowen, D, Symeonidis, A, MIttelmann, M, Stauder, R, Čermák, J, Sanz, G, Langemeijer, S, Malcovati, L, Germing, U, Itzykson, R, Guerci-Bresler, A, Culligan, D, Kotsianidis, I, Koinig, KA, van Marrewijk, C, Crouch, S, de Witte, T & Hellstrom-Lindberg, E 2022, 'Erythropoietin stimulation agents significantly improves outcome in lower risk MDS', HemaSphere, vol. 6, S168, pp. 69-70. https://doi.org/10.1097/01.hs9.0000843564.40783.b4

TY - JOUR

T1 - Erythropoietin stimulation agents significantly improves outcome in lower risk MDS

AU - Garelius, H K G

AU - Smith, Alexandra Gwen

AU - Bagguley, Timothy Charles

AU - Taylor, Adele

AU - Fenaux, Pierre

AU - Bowen, D.

AU - Symeonidis, Argyris

AU - MIttelmann, M

AU - Stauder, R

AU - Čermák, Jaroslav

AU - Sanz, Guillermo

AU - Langemeijer, Saskia

AU - Malcovati, Luca

AU - Germing, Ulrich

AU - Itzykson, Raphael

AU - Guerci-Bresler, Agnès

AU - Culligan, Dominic

AU - Kotsianidis, Ioannis

AU - Koinig, Karin A.

AU - van Marrewijk, Corine

AU - Crouch, Simon

AU - de Witte, Theo

AU - Hellstrom-Lindberg, E

PY - 2022/6

Y1 - 2022/6

N2 - The EUMDS Registry started in 2008 as a prospective, non-interventional longitudinal study, enrolling newly diagnosed patients with IPSS low or intermediate-1 MDS from 16 European countries and Israel.

AB - The EUMDS Registry started in 2008 as a prospective, non-interventional longitudinal study, enrolling newly diagnosed patients with IPSS low or intermediate-1 MDS from 16 European countries and Israel.

U2 - 10.1097/01.hs9.0000843564.40783.b4

DO - 10.1097/01.hs9.0000843564.40783.b4

M3 - Meeting abstract

SN - 2572-9241

VL - 6

SP - 69

EP - 70

JO - HemaSphere

JF - HemaSphere

M1 - S168

T2 - EHA2022 Hybrid Congress

Y2 - 9 June 2022 through 12 June 2022

ER -